1190TiP SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab + tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT)

Previously the standard of care for patients (pts) with locally advanced, unresectable, stage III NSCLC has been cCRT; however, 5-year overall survival (OS) rates are poor. Durvalumab (durva) is approved for pts without progressive disease (PD) after cCRT. However, long-term OS data are not yet available. Further evaluation of novel cancer immunotherapy combinations should be explored. Targeted inhibition of the PD-L1/PD-1 pathway may be further amplified by combining with novel anti-TIGIT agents such as tiragolumab (tira).